Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Esophageal Neoplasms 3Advanced Solid Tumor 3Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Simpson-Golabi-Behmel syndrome 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm, Residual 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Metastatic Solid Tumors 1Melanoma 1Lymphoma, Non-Hodgkin 1Head and Neck Neoplasms 1Esophageal Squamous Cell Carcinoma 1Diabetes Mellitus 1Colorectal Neoplasms 1Cholangiocarcinoma 1Advanced Solid Tumour 1Advanced Solid Tumors 1Advanced Malignancies 1Adenocarcinoma Of Esophagus 1

Interventions

zanidatamab 1tislelizumab 1sitravatinib 1pamiparib 1lenvatinib 1Temozolomide 1Midazolam 1HMPL-013 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignancies × tislelizumab × 30 days × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡